Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.